This site is intended only for healthcare professionals resident in Egypt




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information



Clinical Information​Stroke Prevention in Atrial Fibrillation​Morbidity and Mortality​Efficacy​Aristophanes​Safety​Real-world Data​Guideline recommendations​Persistence and Adherence​Dosing​Summary​Venous Thromboembolism TreatmentEfficacySafety​Real-world Data​Guideline recommendationsDosing​Venous Thromboembolism PreventionEfficacy​Safety​Dosing​Eliquis Important Safety InformationEliquis Abbreviated Prescribing Information (2.5 mg)​Eliquis Abbreviated Prescribing Information (5 mg) Support & Services​ Support & Services​ Self-detail presentations​ Webinars​ MaterialsVideos​

It is the duration of time from initiation to discontinuation of therapy. It is distinct from adherence, which is the extent to which patients conform to physicians’ recommendations relating to timing, dose and frequency of medication taking.3

*In ARISTOTLE, 25.3% of the patients discontinued in the Eliquis® group, with 3.6% of the discontinuations due to death, vs. 27.5% of patients discontinuing in the warfarin group, with 3.8% due to death (P=0.001).2​


Study design​5

Time frame: 22 August 2011 - 31 December 2015.​
Population: A total of 54,321 NOAC-naïve patients with NVAF were identified from nationwide administrative registries.​
Analysis: Retrospective cohort analysis. HRs for non-persistence were calculated using​ Eliquis® as reference. Cox regression models were adjusted for age, sex, calendar year,​ variables in the CHA2DS2-VASc and HAS-BLED scores, and switch of OAC treatment. For all analyses, Eliquis® was used as reference.​

†Non-persistence was defined as no claim for the same as well as for any OAC for at least 30 days following the end of last OAC treatment period (i.e., a treatment gap of more than 30 days).5


‡Persistence was calculated as the proportions of patients on each drug who were alive at the end of 6-month intervals until December 31, 2014, and who claimed the treatment in question during this interval.​6

ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; CHA2DS2-VASc: congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65-74 years, sex category; CI: confidence interval; HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly >65 years, drugs/alcohol concomitantly; INR: International Normalized Ratio; NOAC: non-vitamin K antagonist oral anticoagulant; OAC: oral anticoagulant; OR: odds ratio; US: United States.

References:  1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Cramer JA, Roy A, Burrell A, et al.Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7. 4. Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2). pii: e003074. 5. Lamberts M, Staerk L, Olesen JB, et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life danish patients. J Am Heart Assoc. 2017;6(2). pii: e004517.  6. Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with​ atrial fibrillation. Eur J Clin Pharmacol. 2016;72(3):329-338.

Explore more​VTE prevention Dosing Learn more Loading
Click here for Eliquis® 2.5mg Prescribing Information

Click here for Eliquis® 5mg Prescribing Information

Invalidation Date : 21/08/2024​
Quick Links
SPAF Persistence and Adherence​
Learn moreLoading
VTE treatment Guideline
Learn more Loading

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 

Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.

You are leaving the Pfizer for Professionals website
​You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.
For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.

If you select ‘No’, you will be redirected to, the global Pfizer website.

I confirm that I am a healthcare professional resident in Egypt.


Yes No
You are leaving the Pfizer for Professionals website You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.